Pharmacogenetic associations of CYP2D6 and CYP2C19 variants with anticholinergic drug burden and hyposalivation
Genetic variation in <i>CYP2D6</i> contributes to interindividual differences in systemic anticholinergic burden and hyposalivation. Pharmacogenetic profiling of CYP450 genes may help identify patients at risk of xerostomia from anticholinergic therapy, supporting more personalized and optimized anticholinergic prescribing.
Authors
- Olga A. Korczeniewska (ORCID: https://orcid.org/0000-0001-8399-794X)
- Szilvia Arany (ORCID: https://orcid.org/0000-0002-0021-7088)
- Tong Tong Wu (ORCID: https://orcid.org/0000-0002-1175-9923)
- Scott R. Diehl (ORCID: https://orcid.org/0000-0003-2973-2910)
- Abdul Basir Barmak (ORCID: https://orcid.org/0000-0002-7067-9712)
- Eli Eliav (ORCID: https://orcid.org/0000-0002-8801-5842)
Institutions
- Rutgers, The State University of New Jersey (US)
- Carestream (United States) (US)
- University of Rochester (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fphar.2025.1713345
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00